Mirae Asset Global Investments Co., Ltd. Halozyme Therapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $22.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,582 shares of HALO stock, worth $273,316. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,582
Previous 3,800
20.58%
Holding current value
$273,316
Previous $198,000
32.32%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding HALO
# of Institutions
521Shares Held
123MCall Options Held
208KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$1.05 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$768 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$347 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$241 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$222 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.31B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...